Emerging Company Profile
Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further
Emerging Company Profile: newco to bring asset-centricity to pharma scale
Medicxi launches Centessa with 10 single-asset subsidiaries to provide biotech-like growth with pharma-scale risk profile.
Centessa, launched today, is the latest iteration of investors and pharma veterans toying with newco models that could capitalize on the learnings of the last decade and bring greater efficiencies to the conversion of ideas to products.
The company, launched by Medicxi and a syndicate of 15 blue chip biopharma investors, is bundling 10 asset-centric Medicxi portfolio companies under one umbrella, with the philosophy that it will lower the risk profile for investors while providing each subsidiary with the opportunity to take their programs further, and retain more of the upside value than they could have had if they’d remained independent.
Centessa Pharmaceuticals Inc. is led by